BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal
With Ascendis Pharma entering the achondroplasia space last month and BridgeBio on deck, BioMarin faces competition. Adding to the pressure, the company suffered a setback Monday when it halted two studies of Voxzogo in other growth-related conditions following multiple cases of hip injuries in other trials of the drug.
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal Read More »
